Search Results - "Kersten, Marie J."

Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up by Hübel, Kai, Bower, Mark, Aurer, Igor, Bastos‐Oreiro, Mariana, Besson, Caroline, Brunnberg, Uta, Cattaneo, Chiara, Collins, Simon, Cwynarski, Kate, Pria, Alessia D., Hentrich, Marcus, Hoffmann, Christian, Kersten, Marie J., Montoto, Silvia, Navarro, Jose‐Tomas, Oksenhendler, Eric, Re, Alessandro, Ribera, Josep‐Maria, Schommers, Philipp, Tresckow, Bastian, Buske, Christian, Dreyling, Martin, Davies, Andy

“…Highlights This EHA–ESMO Clinical Practice Guideline provides key recommendations for managing HIV‐associated lymphomas. The guideline covers clinical, imaging…”
Get full text

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma by Bishop, Michael R, Dickinson, Michael, Purtill, Duncan, Barba, Pere, Santoro, Armando, Hamad, Nada, Kato, Koji, Sureda, Anna, Greil, Richard, Thieblemont, Catherine, Morschhauser, Franck, Janz, Martin, Flinn, Ian, Rabitsch, Werner, Kwong, Yok-Lam, Kersten, Marie J, Minnema, Monique C, Holte, Harald, Chan, Esther H.L, Martinez-Lopez, Joaquin, Müller, Antonia M.S, Maziarz, Richard T, McGuirk, Joseph P, Bachy, Emmanuel, Le Gouill, Steven, Dreyling, Martin, Harigae, Hideo, Bond, David, Andreadis, Charalambos, McSweeney, Peter, Kharfan-Dabaja, Mohamed, Newsome, Simon, Degtyarev, Evgeny, Awasthi, Rakesh, del Corral, Christopher, Andreola, Giovanna, Masood, Aisha, Schuster, Stephen J, Jäger, Ulrich, Borchmann, Peter, Westin, Jason R

“…A randomized trial comparing the CD19-specific CAR T-cell therapy tisagenlecleucel with salvage chemotherapy followed by high-dose therapy and autologous…”
Get full text

Confused about Confusion by Spanjaart, Anne M, van der Valk, Fleur M, van Rooijen, Geeske, Brouwer, Matthijs C, Kersten, Marie J

“…Confusion developed in a 49-year-old woman with relapsed diffuse large B-cell lymphoma within days after she received CAR-T therapy. She had difficulty putting…”
Get full text

Treatment of relapsed and refractory Waldenstrom Macroglobulinemia by Amaador, Karima, Kersten, Marie J., Minnema, Monique C., Vos, Josephine M. I.

“…Waldenström's Macroglobulinemia (WM) is a rare type of indolent non-Hodgkin lymphoma (NHL) that remains incurable. Several effective agents such as monoclonal…”
Get full text

Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data by Sweegers, Maike G, Altenburg, Teatske M, Brug, Johannes, May, Anne M, van Vulpen, Jonna K, Aaronson, Neil K, Arbane, Gill, Bohus, Martin, Courneya, Kerry S, Daley, Amanda J, Galvao, Daniel A, Garrod, Rachel, Griffith, Kathleen A, Van Harten, Wim H, Hayes, Sandra C, Herrero-Román, Fernando, Kersten, Marie J, Lucia, Alejandro, McConnachie, Alex, van Mechelen, Willem, Mutrie, Nanette, Newton, Robert U, Nollet, Frans, Potthoff, Karin, Schmidt, Martina E, Schmitz, Kathryn H, Schulz, Karl Heinz, Sonke, Gabe, Steindorf, Karen, Stuiver, Martijn M, Taaffe, Dennis R, Thorsen, Lene, Twisk, Jos W, Velthuis, Miranda J, Wenzel, Jennifer, Winters-Stone, Kerri M, Wiskemann, Joachim, Chin A Paw, Mai J, Buffart, Laurien M

“…To optimally target exercise interventions for patients with cancer, it is important to identify which patients benefit from which interventions. We conducted…”
Get more information

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) by Lugtenburg, Pieternella Johanna, de Nully Brown, Peter, van der Holt, Bronno, D'Amore, Francesco A, Koene, Harry R, de Jongh, Eva, Fijnheer, Rob, van Esser, Joost W, Böhmer, Lara H, Pruijt, Johannes F, Verhoef, Gregor E, Hoogendoorn, Mels, Bilgin, Memis Y, Nijland, Marcel, van der Burg-de Graauw, Nicole C, Oosterveld, Margreet, Jie, Kon-Siong G, Larsen, Thomas Stauffer, van der Poel, Marjolein W, Leijs, Maria B, Silbermann, Matthijs H, van Marwijk Kooy, Marinus, Beeker, Aart, Kersten, Marie J, Doorduijn, Jeanette K, Tick, Lidwine W, Brouwer, Rolf E, Lam, King H, Burggraaff, Coreline N, de Keizer, Bart, Arens, Anne I, de Jong, Daphne, Hoekstra, Otto S, Zijlstra-Baalbergen, Josée M

“…Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with…”
Get full text

Latent human herpesvirus 6 is reactivated in CAR T cells by Lareau, Caleb A., Yin, Yajie, Maurer, Katie, Sandor, Katalin D., Daniel, Bence, Yagnik, Garima, Peña, José, Crawford, Jeremy Chase, Spanjaart, Anne M., Gutierrez, Jacob C., Haradhvala, Nicholas J., Riberdy, Janice M., Abay, Tsion, Stickels, Robert R., Verboon, Jeffrey M., Liu, Vincent, Buquicchio, Frank A., Wang, Fangyi, Southard, Jackson, Song, Ren, Li, Wenjing, Shrestha, Aastha, Parida, Laxmi, Getz, Gad, Maus, Marcela V., Li, Shuqiang, Moore, Alison, Roberts, Zachary J., Ludwig, Leif S., Talleur, Aimee C., Thomas, Paul G., Dehghani, Houman, Pertel, Thomas, Kundaje, Anshul, Gottschalk, Stephen, Roth, Theodore L., Kersten, Marie J., Wu, Catherine J., Majzner, Robbie G., Satpathy, Ansuman T.

“…Cell therapies have yielded durable clinical benefits for patients with cancer, but the risks associated with the development of therapies from manipulated…”
Get full text

Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma by Kuipers, Maria T, Spanjaart, Anne M, Bonifazi, Francesca, diBlasi, Roberta, Zinzani, Pier L, Thieblemont, Catherine, Baudet, Mathilde, Biemond, Bart J, Kok, Wouter E M, Kersten, Marie J

Get full text

Cortical myoclonic tremor after chimeric antigen receptor T-cell therapy by Swinnen, Bart E. K. S., van Rootselaar, Anne-Fleur, Spanjaart, Anne M., de Bie, Rob M. A., Kersten, Marie J., van de Beek, Diederik, Brouwer, Matthijs C., Dijk, Joke M.

Get full text

Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment by Koens, Lianne, Ven, Peter M, Hijmering, Nathalie J, Kersten, Marie J, Diepstra, Arjan, Chamuleau, Martine, Jong, Daphne

“…Aims CD30 immunohistochemistry (IHC) in malignant lymphoma is used for selection of patients in clinical trials using brentuximab vedotin, an antibody…”
Get full text

Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing by Arulogun, Suzanne O., Brian, Duncan, Goradia, Harshita, Cooney, Aaron, Menne, Tobias, Koo, RayMun, O'Neill, Aideen T., Vos, Josephine M. I., Pratt, Guy, Turner, Deborah, Marshall, Kirsty, Manos, Kate, Anderson, Claire, Gavriatopoulou, Maria, Kyriakou, Charalampia, Kersten, Marie J., Minnema, Monique C., Koutoumanou, Eirini, El‐Sharkawi, Dima, Linton, Kim, Talaulikar, Dipti, McCarthy, Helen, Bishton, Mark, Follows, George, Wechalekar, Ashutosh, D'Sa, Shirley P.

“…Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinemia (WM). The impact dose of Bendamustine dose on…”
Get full text

Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients by Buske, Christian, Castillo, Jorge  J., Abeykoon, Jithma  Prasad, Advani, Ranjana, Arulogun, Suzanne  O., Branagan, Andrew  R., Cao, Xinxin, D'Sa, Shirley, Hou, Jian, Kapoor, Prashant, Kastritis, Efstathios, Kersten, Marie  J., LeBlond, Veronique, Leiba, Merav, Matous, Jeffrey  V., Paludo, Jonas, Qiu, Lugui, Tam, Constantine  S., Tedeschi, Alessandra, Thomas, Sheeba  K., Tohidi-Esfahani, Ibrahim, Varettoni, Marzia, Vos, Josephine  M., Garcia-Sanz, Ramon, San-Miguel, Jesus, Dimopoulos, Meletios  A., Treon, Steven  P., Trotman, Judith

“…Consensus Panel 1 (CP1) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management…”
Get full text

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma by Jaeger, Ulrich, Tam, Constantine S., Borchmann, Peter, McGuirk, Joseph P., Johansen, Marianne, Waller, Edmund K., Jaglowski, Samantha, Andreadis, Charalambos, Foley, Stephen R., Westin, Jason R., Fleury, Isabelle, Ho, P. Joy, Mielke, Stephan, Teshima, Takanori, Salles, Gilles, Schuster, Stephen J., He, Fiona, Maziarz, Richard T., Mayer, Sebastian, Makita, Shinichi, Kersten, Marie J., Ghosh, Monalisa, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Goto, Hideki, Colicino, Silvia, Agarwal, Abhijit, Lobetti-Bodoni, Chiara, Bishop, Michael R.

Get full text

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia by Deenik, Wendy, van der Holt, Bronno, Verhoef, Gregor E.G., Smit, Willem M., Kersten, Marie J., Kluin-Nelemans, Hanneke C., Verdonck, Leo F., Ferrant, Augustin, Schattenberg, Anton V. M.B., Janssen, Jeroen J. W.M., Sonneveld, Pieter, van Marwijk Kooy, Marinus, Wittebol, Shulamit, Willemze, Roelof, Wijermans, Pierre W., Westveer, Petra H.M., Beverloo, H. Berna, Valk, Peter, Löwenberg, Bob, Ossenkoppele, Gert J., Cornelissen, Jan J.

“…The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase…”
Get full text

Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity by García, Alberto, Kelm, Malte, Silva, María Gomes, Sánchez‐González, Javier, Sánchez, Pedro L., López‐Fernández, Teresa, Córdoba, Raul, Camus, Vincent, Smink, Jouke, Ferreira, Antonio, Kersten, Marie J., Bolaños, Natacha, Escalera, Noemi, Gómez‐Talavera, Sandra, Quesada, Antonio, Rosselló, Xavier, Ibanez, Borja, Martín, Alejandro, López, Javier, Peñarrubia, María Jesús, Vadillo, Irene Sánchez, Bastos, Mariana, Ubieto, Ana Jiménez, Barca, María Belén Navarro Eva González, Rodríguez, Guillermo, Berruezo, Antonio, Dacher, Jean‐Nicolas, Alonso, Arancha, Rivas, Jose Angel Hernández, Suarez, Julio García, Lebreton, Pierre, Rodríguez, Irene Sempere, Carretero, Jesús Molina, Vaquero, Ignacio Polo, Manchón, Ángel Franch, Delgado, Tamara Fernández, Fernández, Samuel Pérez, Menéndez, Manuel Desco, Álvarez, María López, Viyuela, Alba María Vega, Gambarte, Laura Pardo, Giles, Daniel Morillo, Ángeles Pérez Saenz, María, Palafox, Ester Macía, Dietrich, Sascha, Polzin, Amin, Voss, Fabian, Kamper, Peter Martin Hjørnet, Kjær, Sanne Nagstrup, Andersen, Katrine Frikke, Céu Trindade, Maria, Viegas, Diana, Harres, Vanessa, Ercan, Ece, Guzmán, Álvaro Navarro, Gonçalves, Fernando, Tilly, Hervé, Jardin, Fabrice, Stamatoullas, Aspasia, Zduniak, Alexandra, Lebreton, Pierre, Lepretre, Stephane, Lenain, Pascal, Bouclet, Florian, Lanic, Helene, Lemasle, Emilie, Dubois, Sydney, Brehar, Oana, Richard, Doriane, Belilita, Ridha, Nederveen, Aart J, Eyiis, Esra, Heer, Koen, Agea, Esther, Baladrón, Carlos, Villar Moro, Candelas Perez, Gutiérrez, Norma Carmen Gutiérrez, Pacho, Leticia Vicente, Elorza, Begoña Navas, Martín, Javier Cucharero, Gil, Raquel, García, Mireia Bañuls, Peña, Alba Gutiérrez, Lopera, Sandra Gómez, Gotarredona, María Del Pilar Serrano, Pañella, Marina Huguet, Normant, Sébastien, Torre, Alejandra Segado, Mora, Mariana Tercero, Infante, María Stefania, Gascón, Isabel González, Novas, Carolina Muñoz, Ordoño, Raquel Fernandez, Almendral, Adrian Porcel, Ballester, Elena Flores, Jomarron, Isabel Gutierrez, Guerrero, Yolanda Martin, Gutierrez, Paola Villafuerte, Rubio, Montserrat Lopez, Picard, Angélique

“…Aims There is a lack of therapies able to prevent anthracycline cardiotoxicity (AC). Remote ischaemic conditioning (RIC) has shown beneficial effects in…”
Get full text

Interobserver variation in CD 30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment by Koens, Lianne, van de Ven, Peter M, Hijmering, Nathalie J, Kersten, Marie J, Diepstra, Arjan, Chamuleau, Martine, de Jong, Daphne

“…Aims CD 30 immunohistochemistry ( IHC ) in malignant lymphoma is used for selection of patients in clinical trials using brentuximab vedotin, an antibody…”
Get full text

Report of consensus panel 1 from the 11 th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients by Buske, Christian, Castillo, Jorge J, Abeykoon, Jithma Prasad, Advani, Ranjana, Arulogun, Suzanne O, Branagan, Andrew R, Cao, Xinxin, D'Sa, Shirley, Hou, Jian, Kapoor, Prashant, Kastritis, Efstathios, Kersten, Marie J, LeBlond, Veronique, Leiba, Merav, Matous, Jeffrey V, Paludo, Jonas, Qiu, Lugui, Tam, Constantine S, Tedeschi, Alessandra, Thomas, Sheeba K, Tohidi-Esfahani, Ibrahim, Varettoni, Marzia, Vos, Josephine M, Garcia-Sanz, Ramon, San-Miguel, Jesus, Dimopoulos, Meletios A, Treon, Steven P, Trotman, Judith

“…Consensus Panel 1 (CP1) of the 11 International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of…”
Get full text